Approval Probability 71%
TA Base Rate26%
Adjusted LOA41%
ML RiskLOW_RISK
| NCT ID | Title | Phase | Status | Enrollment | Velocity | Design | Start | Completion | Last Updated | Sites | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|
| NCT07119125 | A First-in-human, 3-part Study of MRT-8102 in Healthy Participants and Participants at Cardiovascular Risk With Elevated CRP | PHASE1 | ACTIVE NOT_RECRUITING | 100 | — | — | Jun 27, 2025 | Jul 1, 2026 | Jun 4, 2026 | 4 | United States |
Incidence of treatment-emergent adverse events by type severity seriousness and relationship to treatment and changes from baseline in safety-related clinical lab parameter, vital signs 12-lead ECGs and PEs
Incidence of treatment-emergent adverse events by type severity seriousness and relationship to treatment and changes from baseline in safety-related clinical lab parameter, vital signs 12-lead ECGs and PEs
Incidence of treatment-emergent adverse events by type severity seriousness and relationship to treatment and changes from baseline in safety-related clinical lab parameter, vital signs 12-lead ECGs and PEs
| Arm | Type | Description |
|---|---|---|
| Part 1: Single Ascending Dose (MRT-8102) | EXPERIMENTAL | Single Dose of MRT-8102 |
| Part 1: Single Ascending Dose (Placebo) | PLACEBO_COMPARATOR | Single Dose of Placebo |
| Part 2: Multiple Ascending Dose (MRT-8102) | EXPERIMENTAL | 7-day Daily Dose of MRT-8102 |
| Part 2: Multiple Ascending Dose (Placebo) | PLACEBO_COMPARATOR | 7-day Daily Dose of Placebo |
| Part 3: elevated CRP (MRT-8102) | EXPERIMENTAL | 28-day Daily Dose of MRT-8102 |
| Part 3: elevated CRP (Placebo) | PLACEBO_COMPARATOR | 28-day Daily Dose of Placebo |
| Name | Type | Description |
|---|---|---|
| MRT-8102 | DRUG | Oral capsules |
| Placebo | DRUG | Oral capsules |
Eligibility Criteria: Inclusion Criteria (all parts) * Healthy, adult, male or females 18-65 years of age * Non-smoker who has not used nicotine- and tobacco -containing products for at least 3 months prior to start of study * Able to swallow oral medications * Abstain from caffeine- and methylxan...